Istesso, IP Group’s largest private life sciences holding (c 11% of end-June 2024 portfolio value), has announced the results of its Phase IIb clinical trial of leramistat in rheumatoid arthritis (RA). Leramistat demonstrated a statistically significant reduction in bone erosion, the key secondary

27 Feb 2025
Examining Istesso’s Phase IIb trial results

Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Examining Istesso’s Phase IIb trial results
IP Group plc (IPO:LON) | 57.4 0.3 0.9% | Mkt Cap: 524.1m
- Published:
27 Feb 2025 -
Author:
Milosz Papst -
Pages:
3 -
Istesso, IP Group’s largest private life sciences holding (c 11% of end-June 2024 portfolio value), has announced the results of its Phase IIb clinical trial of leramistat in rheumatoid arthritis (RA). Leramistat demonstrated a statistically significant reduction in bone erosion, the key secondary